Access Publications and Meeting Presentations Below

McGeehan G., (2020, April). “A first-in-class Menin-MLL1 antagonist for the treatment of MLL-r and NPM1 mutant leukemias.” Slides presented at the 2020 American Association for Cancer Research Virtual Annual Meeting I.

Krivstov, A., (2019, December) “A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of of MLL-Rearranged Leukemia.”

McGeehan, G., (2019, January) “Targeting the Menin MLL1 Interaction Site as a Treatment for Mixed Lineage Leukemia rearranged (MLL r) and NPM1c+ AML.” Slides presented at Clinical Translation of Epigenetics in Cancer Therapy Conference, Litchfield Park, AZ.

Armstrong S. (2018). “VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1c⁺ leukemia.” Slides presented at European School of Hematology Conference, Stockholm, Sweden.

Armstrong S. (2018, December). “Targeting Epigenetic Mechanisms to Reverse Stem Cell Programs in Cancer.” Slides presented at the American Society of Hematology Annual Meeting, San Diego, CA.

Uckelmann, H. (2018, December). “MLL-Menin inhibition reverses pre-leukemic progenitor self-renewal induced by NPM1 mutations and prevents AML development.” Slides presented at the American Society of Hematology Annual Meeting, San Diego, CA.

McGeehan, G. (2018, July). “Targeting the Menin-MLL1 Interaction Site as a Treatment for Mixed Lineage Leukemia-rearranged (MLL-r) and NPM1c+ AML.” Slides presented at the Molecular Therapeutics of Cancer Research Conference, Sundance, UT.

Krivtsov A. V., J. Y. Gadrey, et al. (2018, April). “VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1c⁺ leukemia.” Slides presented at the American Association for Cancer Research Annual Meeting, Chicago, IL.

Lock R. B., K. Evans, et al. (2018, April). “Pediatric Preclinical Testing Consortium evaluation of the menin inhibitor, VTP-50469, against xenograft models of MLL-rearranged infant acute lymphoblastic leukemia.” Poster presented at the American Association for Cancer Research Annual Meeting, Chicago, IL.

Azad N., D. Rasco, et al. (2020, April). “SNDX-6352-0502 – A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of axatilimab (SNDX-6352) monotherapy in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors.” Slides presented at the 2020 American Association for Cancer Research Virtual Annual Meeting I.

Tolcher A. W., D. Rasco, et al. (2020, April). “SNDX-6352-0502: A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 in combination with durvalumab in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors.” Slides presented at the 2020 American Association for Cancer Research Virtual Annual Meeting I.

Tiessen R., A. Visser, et al. (2017, November). “First in human, single ascending dose study in healthy volunteers of SNDX-6352, a humanized IgG4 monoclonal antibody targeting colony stimulating factor-1 receptor (CSF-1R).” Poster presented at the Society for the Immunotherapy of Cancer Annual Meeting, National Harbor, MD.

Ordentlich P., P. Vajjah, et. al. (2016, November). “Targeting colony stimulating factor- 1 receptor (CSF-1R) with SNDX-6352, a novel anti-CSF-1R targeted antibody.” Poster presented at the Society for the Immunotherapy of Cancer Annual Meeting, National Harbor, MD.

Ruffell B., and L. Coussens (2015). “Macrophages and Therapeutic Resistance in Cancer.” Cancer Cell. 27(4):462-72.

Cadoo K., M. Meyers, et al. (2019, June). “ENCORE 603: A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients with advanced and recurrent epithelial ovarian cancer.” Slides presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL.

Sullivan R., S. Moschos, et al. (2019, April). “Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD-1 therapy.” Slides presented at the American Association for Cancer Research Annual Meeting, Atlanta, GA.

Ordentlich P., L. Wang, et al. (2019, March). “Identification of gene signatures associated with response in a Phase 2 trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy.” Slides presented at the American Association for Cancer Research Annual Meeting, Atlanta, GA.

Nandre R., V. Verma, et al. (2018, November). “Entinostat Increases the Frequency of Tumor-Specific Effector T-cells and Their Functionality is Enhanced by Anti-OX40 Leading to Durable anti-Tumor Effects.” Poster presented at the Society for the Immunotherapy of Cancer Annual Meeting, Washington, DC.

Hellmann M., P. Janne, et al. (2018, September). “Efficacy/safety of entinostat (ENT) and pembrolizumab (PEMBRO) in NSCLC patients previously treated with anti-PD-(L)1 therapy.” Slides presented at the IASLC 19th World Conference on Lung Cancer, Toronto, Canada.

Agarwala S. et al. (2018, June) “Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody.” Poster presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL.

Azad N. et al. (2018, June). “ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.” Poster presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL.

Gandhi L. et al. (2018, June). “Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.” Poster presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL.

Tolcher A., M. L. Meyers, et al. (2018, April). “Safety, Efficacy, and Immune Correlates of Alternative Doses and Schedules of Entinostat Combined With Pembrolizumab in Patients With Advanced Solid Tumors – Results From SNDX-275-0141 Phase I Trial.” Slides presented at the American Association for Cancer Research Annual Meeting, Chicago, IL.

Wang L., D. Chen F., et al. (2018, April). “Enhanced Anti-tumor Activity of the Combination of Entinostat and NKTR-214 in Renal and Colon Cancer Tumor Models.” Poster presented at the American Association for Cancer Research Annual Meeting, Chicago, IL.

Krieg C., M. Nowicka, et al. (2018) “High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy.” Nat Med. 24(2), 144–153.

Pili R., D. Quinn, et at. (2017). “Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).” Clin Cancer Res. 23(23), 7199-7208

Johnson M., D. Gabrilovich, et al. (2017, November). “Analysis of biomarkers from a cohort of advanced melanoma patients treated with entinostat (ENT) and pembrolizumab (PEMBRO) previously exposed to immune checkpoint inhibition.” Poster presented at the Society for the Immunotherapy of Cancer Annual Meeting, National Harbor, MD.

Gandhi L.., M. Johnson, et al. (2017, November). “ENCORE-601: Phase 1b/2 study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer.” Poster and slides presented at the Society for the Immunotherapy of Cancer Annual Meeting, National Harbor, MD.

• Click here to view the poster.
• Click here to view the oral presentation.

 
Orillion A., A. Hashimoto, et al. (2017). “Entinostat neutralizes myeloid derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma.” Clin Cancer Res. DOI: 10.1158/1078-0432.CCR-17-0741

Johnson M. et al. (2017, June). “ENCORE 601: A Phase 2 study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma.” Poster presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL.

Johnson M., A. Adjei, et al. (2016, November). “Dose-escalation/confirmation results of ENCORE 601, a Phase 1b/2, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non–small cell lung cancer (NSCLC).” Poster presented at the Society for the Immunotherapy of Cancer Annual Meeting, National Harbor, MD.

Gameiro SR, AS Malamas, et al. (2016).  “Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.” Oncotarget. 7(7):7390-402.

Shen, L., A. Orillion, R. Pili. (2016). “Histone deacetylase inhibitors as immunomodulators in cancer therapeutics.” Epigenomics. 8(3):415-28.

Park J., S. Thomas, and P. Munster. (2015). “Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy”. Epigenomics. 7(4):641-52.

Kim, K., A. Skora, et al. (2014). “Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.” PNAS. 111(32):11774-9.

Youn JI, V. Kumar, et al. (2013). “Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer.” Nat. Immunol. 14(3): 211–220.

Zhu S., C. Denman, et al. (2013). “The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.” Pharm. Res. 32(3): 779–92.

Shen, L., M. Ciesielksi, et al. (2012). “Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.” PLoSOne. 7(1): e30815.

Juergens RA, J. Wrangle, et al. (2011). “Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.” Cancer Discov. 1(7): 598–607.

Yeruva, S., F. Zhao et al. (2018). “E2112: randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.” NPJ Breast Cancer. 4:1. doi: 10.1038/s41523-017-0053-3. eCollection 2018.

Merino, VF., N. Nguyen, et al. (2016). “Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer.” Cancer Res. 76(7):2013-24.

Tomita, Y., M. Lee, et al. (2016). “The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo controlled phase II trial of exemestane with or without entinostat.” OncoImmunology. DOI: 10.1080/2162402X.2016.1219008

Schech A, A. Kazi, et al. (2015). “Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells.” Mol Cancer Ther. 14(8): 1848–1857.

Connolly R. et al. (2014, December). “E2112: A randomized phase III trial of endocrine therapy plus entinostat or placebo in patients with hormone receptor-positive advanced breast cancer.” Poster presented at the San Antonio Breast Cancer Symposium, San Antonio, TX.

Sabnis, G., O. Goloubeva, et al. (2013). “HDAC inhibitor entinostat restores responsiveness of letrozole resistant MCF-7Ca xenografts to AIs through modulation of Her-2.” Mol Cancer Ther. 12(12):2804-16.

Shah, P., Gau, Y., Sabnis, G. (2013). “Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.” Breast Canc Res Treat. 143(1):99-111.

Yardley, D., R. Ismail-Khan, et al. (2013). “A randomized phase 2, double-blind, placebo-controlled study of exemestane with and without entinostat (SNDX-275) in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a non-steroidal aromatase inhibitor.” J Clin Oncol. 31(17):2128-35.

Connolly, R., and V. Stearns (2012). “Epigenetics as a therapeutic target in breast cancer.” J Mammary Gland Biol Neoplasia. 17(3-4):191-204.

Srivastava, R., R. Kurzrock, et al. (2010). “MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.” Mol Cancer Ther. 9(12):3254-66.